The global infertility drugs market is poised for steady growth, with its market size valued at USD 3,699.8 million in 2023. The market is projected to reach USD 6,814.68 million by 2033, expanding at a compound annual growth rate (CAGR) of 6.3% over the forecast period.
The increasing prevalence of infertility among both men and women is a key factor driving the demand for infertility drugs. As fertility challenges become more widespread due to various lifestyle, environmental, and genetic factors, the need for effective pharmaceutical solutions continues to grow.
The increasing prevalence of infertility is driving the demand for effective infertility treatments. Both women and men are equally affected by infertility issues, contributing to the rising need for innovative and accessible infertility drug solutions.
As infertility concerns continue to rise globally, there has been an unprecedented surge in the demand for cutting-edge infertility drugs. Both men and women are equally affected by infertility, with causes ranging from age-related factors to specific health conditions.
Key Takeaways from Infertility Drugs Market Study
- The infertility drugs market is expected to record a CAGR of 6.3% over the forecast period.
- According to estimates, the infertility drugs market in North America may remain strong throughout the length of the forecast period.
- The gonadotropins segment dominated the infertility drugs market with a revenue share of 40.1% in 2023 and is expected to grow rapidly.
- The women’s segment dominated the market for infertility drugs in 2023 with a revenue share of 71.3%.
Infertility Drugs Market Competitive Landscape:
Several prominent companies dominate this market, including Ferring Pharmaceuticals Inc., Merck KGaA, Bayer AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Theramex, Novartis AG., Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co., Mankind Pharma Ltd., and others.
Sustainable and environmental footprint awareness may drive the choice of active ingredients and materials for the Infertility Drug Market, as well as packaging. By engaging in these activities, manufacturers can expand their product portfolios, expand their geographical reach, and capture a larger share of the market.
In addition to gaining access to the latest markets and advanced technologies, key players can also gain access to new markets by partnering with other companies. In addition, companies can acquire, merge, and diversify their portfolios.
Infertility Drugs Market Segmentation by Category
By Drug Class:
- Gonadotrophins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Biguanides
- Other Drug Classes
By End User:
- Male
- Female
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Other Distribution Channels
By Region Outlook:
- North America
- Latin America
- Europe
- The Middle East and Africa
- East Asia
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube
